Literature DB >> 8194884

Regulation of fibronectin and laminin receptor expression, fibronectin and laminin secretion in human colon cancer cells by transforming growth factor-beta 1.

S Huang1, S Chakrabarty.   

Abstract

Transforming growth factor (TGF)-beta 1 modulates the expression of extracellular matrix (ECM) glycoproteins, fibronectin and laminin and the adhesion of Moser colon cancer cells to these glycoproteins. Since adhesion can be altered through expression of cell-surface receptors, binding affinities of adhesion molecules for receptors, or both, we investigated the effect of TGF-beta 1 on the binding properties of fibronectin and laminin to their cell-surface receptors by saturation binding and Scatchard analyses using radiolabeled fibronectin and laminin. Fibronectin bound to its cell-surface receptor with high affinity (Kd = 1.25 x 10(-9) M), Moser cells had approximately 7.1 x 10(4) fibronectin-binding sites per cell. TGF-beta 1 treatment rapidly up-modulated the number of cell-surface fibronectin-binding sites by 1.9-fold. The binding affinity of fibronectin for the receptor, however, was not altered. Laminin was found to bind to a higher-affinity and a lower-affinity receptor. Moser cells expressed approximately 1.1 x 10(3) higher-affinity laminin-binding sites and approximately 3.1 x 10(4) lower-affinity-binding sites per cell. TGF-beta 1 rapidly increased the expression of the higher-affinity sites 3-fold and the lower-affinity sites 5-fold. The binding affinity of both the higher-affinity and lower-affinity laminin receptors increased 3-fold after 2 and 6 hr of TGF-beta 1 treatment respectively. Concurrent with receptor modulation, TGF-beta 1 induced the secretion of fibronectin and laminin from Moser cells. Northern hybridization analyses showed a concurrent stimulation of the expression of the mRNAs for ligands (fibronectin and laminin) and the mRNAs for the integrin species of the fibronectin and laminin receptors (alpha 5 and alpha 6 subunits). Thus the production of fibronectin and laminin and the expression of their receptors were tightly co-regulated by TGF-beta 1.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8194884     DOI: 10.1002/ijc.2910570522

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  9 in total

1.  Regulation of T-cell interaction with fibronectin by transforming growth factor-beta is associated with altered Pyk2 phosphorylation.

Authors:  A Brill; S Franitza; O Lider; R Hershkoviz
Journal:  Immunology       Date:  2001-10       Impact factor: 7.397

2.  TGF-beta specifically enhances the metastatic attributes of murine lung adenocarcinoma: implications for human non-small cell lung cancer.

Authors:  Paula Fernanda Vázquez; María José Carlini; María Cecilia Daroqui; Lucas Colombo; Mercedes Liliana Dalurzo; David Eduardo Smith; Julieta Grasselli; María Guadalupe Pallotta; Marcelo Ehrlich; Elisa Dora Bal de Kier Joffé; Lydia Puricelli
Journal:  Clin Exp Metastasis       Date:  2013-07-06       Impact factor: 5.150

3.  Transforming growth factor beta suppresses beta-catenin/Wnt signaling and stimulates an adhesion response in human colon carcinoma cells in a Smad4/DPC4 independent manner.

Authors:  Huijun Wang; Shanthi Rajan; Guangming Liu; Subhas Chakrabarty
Journal:  Cancer Lett       Date:  2008-03-25       Impact factor: 8.679

4.  Accumulation of extracellular matrix and developmental dysregulation in the pancreas by transgenic production of transforming growth factor-beta 1.

Authors:  M S Lee; D Gu; L Feng; S Curriden; M Arnush; T Krahl; D Gurushanthaiah; C Wilson; D L Loskutoff; H Fox
Journal:  Am J Pathol       Date:  1995-07       Impact factor: 4.307

5.  Switch of transforming growth factor beta function from tumor suppression to stimulation in adenomatous polyposis coli (APC) knocked-down human colon carcinoma cells.

Authors:  Hongmei Wang; Moltira Promkan; Guangming Liu; Subhas Chakrabarty
Journal:  Cancer Lett       Date:  2008-09-06       Impact factor: 8.679

6.  A novel function for the tumor suppressor p16(INK4a): induction of anoikis via upregulation of the alpha(5)beta(1) fibronectin receptor.

Authors:  T Plath; K Detjen; M Welzel; Z von Marschall; D Murphy; M Schirner; B Wiedenmann; S Rosewicz
Journal:  J Cell Biol       Date:  2000-09-18       Impact factor: 10.539

Review 7.  Serological assessment of collagen fragments and tumor fibrosis may guide immune checkpoint inhibitor therapy.

Authors:  Christina Jensen; Neel I Nissen; Claus S Von Arenstorff; Morten A Karsdal; Nicholas Willumsen
Journal:  J Exp Clin Cancer Res       Date:  2021-10-16

Review 8.  Understanding the functional inflammatory factors involved in therapeutic response to immune checkpoint inhibitors for pan-cancer.

Authors:  Yanmeizhi Wu; Shan Yu; Hong Qiao
Journal:  Front Pharmacol       Date:  2022-09-01       Impact factor: 5.988

9.  Study of in vitro and in vivo effects of 1,6-Bis[4-(4-amino-3-hydroxyphenoxy)phenyl]diamantane (DPD), a novel cytostatic and differentiation inducing agent, on human colon cancer cells.

Authors:  J J Wang; Y F Chang; Y T Chern; C W Chi
Journal:  Br J Cancer       Date:  2003-11-17       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.